Table 2. . Treatment factors.
| Number of treatment courses | CE | Y90 |
|---|---|---|
| 35 | 39 | |
| Type of treatment | ||
| Conventional TACE (n) | 24 | 0 |
| Drug-eluting beads (DEB-TACE) (n) | 7 | 2† |
| – Y90 theraspheres | 4† | 26 |
| – Y90 SIR-spheres | 0 | 11 |
| – Total | 4 | 37 |
| Total hepatic bead treatment (n) | ||
| 1 | 5 | 13 |
| 2 | 5 | 11 |
| 3 | 4 | 0 |
| ≥4 | 2 | 1 |
| Level of branching (n) | ||
| Whole liver | 1 | 0 |
| Lobar | 20 | 29 |
| Segmental | 14 | 4 |
| Lobar/segmental | 0 | 6 |
| Y90 activity delivered | NA | 1.56 GBq (0.41–5.31) |
†Crossover treatment
Y90: Radioembolization; CE: Chemoembolization; DEB: Drug-eluting bead; TACE: Transarterial chemoembolization.